Narrow search
Showing 1 - 7 of 7
Cover Image
The Effect of Changes in Treatment Patterns on Drug Expenditure
Gerdtham, Ulf-G.; Johannesson, Magnus; Gunnarsson, Bo; … - In: PharmacoEconomics 13 (1998) 1 Part 2, pp. 127-134
This paper investigates the effects of changes in drug therapy on drug expenditure in Sweden between 1990 and 1995. Analyses have been carried out for both the aggregate drug expenditure and for drug expenditure according to the main groups of the Anatomical Therapeutic Chemical (ATC)...
Persistent link: https://www.econbiz.de/10005449148
Cover Image
Why Did Drug Spending Increase During the 1990s?: A Decomposition Based on Swedish Data
Gerdtham, Ulf-G.; Lundin, Douglas - In: PharmacoEconomics 22 (2004) 1, pp. 29-42
Objective: To decompose drug spending in Sweden between the years 1990 and 2000. This paper updates a previous study, which looked at the period 1990-1995, by providing an additional 5 years of data (1995-2000) and extending the previous analysis in a number of ways. Methods: The paper builds on...
Persistent link: https://www.econbiz.de/10005590354
Cover Image
Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies
Zethraeus, Niklas; Johannesson, Magnus; Jönsson, Bengt; … - In: PharmacoEconomics 21 (2003) 1, pp. 39-48
No consensus has yet been reached on how to analyse uncertainty in economic evaluation studies where individual patient data are available for costs and health effects. This paper summarises the available results regarding the analysis of uncertainty on the cost-effectiveness plane and argues...
Persistent link: https://www.econbiz.de/10011001517
Cover Image
Price Indices of Drugs and the Switching to New Drugs: Two Empirical Examples
Gerdtham, Ulf-G; Johannesson, Magnus; Gunnarsson, Bo; … - In: PharmacoEconomics 13 (1998) 1 Part 1, pp. 71-80
Standard price indices may not account for the price decrease that results when patients switch to pharmaceutical products for which their demand-reservation price exceeds the price of the new product. In a similar way, standard price indices may not account for the price increase that results...
Persistent link: https://www.econbiz.de/10005590299
Cover Image
Assessment of the Relationship Between Measures of Disease Severity, Quality of Life, and Willingness to Pay in Asthma
Zillich, Alan J.; Blumenschein, Karen; Johannesson, Magnus - In: PharmacoEconomics 20 (2002) 4, pp. 257-265
Objective:The primary objective was to evaluate the relationship between willingness-to-pay (WTP), quality-of-life (QOL), and disease-severity measures in patients with asthma. The hypothesis studied was that patients with asthma with more severe disease are willing to pay more for a...
Persistent link: https://www.econbiz.de/10005590465
Cover Image
Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies
Zethraeus, Niklas; Johannesson, Magnus; Jonsson, Bengt; … - In: PharmacoEconomics 21 (2003) 1, pp. 39-48
No consensus has yet been reached on how to analyse uncertainty in economic evaluation studies where individual patient data are available for costs and health effects. This paper summarises the available results regarding the analysis of uncertainty on the cost-effectiveness plane and argues...
Persistent link: https://www.econbiz.de/10005590468
Cover Image
Urge Incontinence: Quality of Life and Patients' Valuation of Symptom Reduction
O'Conor, Richard M.; Johannesson, Magnus; Hass, Steven L.; … - In: PharmacoEconomics 14 (1998) 5, pp. 531-539
Objective: Previous studies have demonstrated the effect of incontinence, and urge incontinence in particular, on patients' quality of life. This study assessed the effects of urge incontinence on quality of life and measured the value of a reduction in symptoms. Design: A self-administered...
Persistent link: https://www.econbiz.de/10005590522